Scientific Sessions 2025  /  Personalized, Potent, and Precise: The Evolving Drug Landscape in AMI  /  Emerging Therapies in AMI: Targeting Inflammation and Microvascular Obstruction
Logo

American Heart Association

  32
  0

Final ID:

Emerging Therapies in AMI: Targeting Inflammation and Microvascular Obstruction

  • Ridker, Paul  ( BRIGHAM WOMENS HOSPITAL , Boston , Massachusetts , United States )
    • Author Disclosures:
    Paul Ridker: DO have relevant financial relationships ; Research Funding (PI or named investigator):Kowa, Novartis, Pfizer, NovoNordisk:Active (exists now) ; Advisor:Uppton, Bitteroot Bio, Angiowave, Peter Munk University of Toronto, Leducq Foundation:Active (exists now) ; Consultant:Novartis, Novo Nordisk, Agepha, Ardelyx, Arrowhead, AstraZeneca, CSK Behring, Civi Biopharm, GSK, Eil Lilly, New Amsterdam, CardioTherapeutics, Caristo, Tourmaline Bio:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Personalized, Potent, and Precise: The Evolving Drug Landscape in AMI

Monday, 11/10/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
Next-Gen Antiplatelet and Anticoagulant Therapies in AMI: Moving Beyond the Standard of Care

Rymer Jennifer

Beyond Reperfusion: Cardiomyocyte Regeneration in AMI – Hype or Hope?

Pompilio Giulio, Janssens Stefan

More abstracts from these authors:
Canakinumab - can it find a role for CAD?

Ridker Paul

Beyond Lipids: The Current and Future Landscape of Anti-Inflammatory Therapies for ASCVD

Ridker Paul, Ballantyne Christie

You have to be authorized to contact abstract author. Please, Login
Not Available